Treatment for breast cancer (CaB) in the United States has matured as oncologists have formalized protocols around specific patient populations, namely HER2+, HR+/HER2-, and HR-/HER2- (also known as triple negative) CaB. Over the past decade, breakthroughs in treatment have reshaped how CaB is treated as newer therapies such as Herceptin and Tykerb were approved as monotherapy or in combination for specific patient populations. As a result, treatment of CaB is fairly standardized today with specific agents dominating patient share. However, the arrival of newer therapies and combinations of some of these agents may reshape CaB treatment as oncologists and payers seek therapies that have superior efficacy in mostly OS or PFS trial data.
Branded agents covered in this report include:
– Genentech/Roche’s Herceptin (trastuzumab)
– Genentech/Roche’s Perjeta (pertuzumab)
– Roche’s Kadcyla (trastuzumab emtansine)
– Novartis’s Afinitor (everolimus)
– GlaxoSmithKline’s Tykerb (lapatinib)
– Roche’s Avastin (bevacizumab)
– Pfizer’s palbociclib
– Novartis’s buparlisib
– Novartis’s LEE-011
– Tesaro’s niraparib
– BioMarin Pharmaceutical’s BMN-673
– Celldex’s Glembatumumab vedotin
In this report, we explore the use and formulary status of key current therapies for treating CaB and the likely reception of key emerging therapies in a survey of 101 oncologists and 30 managed care organization directors. By understanding the attitudes and expectations of prescribers and payers toward current and emerging CaB therapies, stakeholders can gain an understanding of the treatment paradigm and changing reimbursement climate for treatment of this indication.